Neurent Medical

Executive Summary

Neurent Medical is an Irish medical device company developing minimally invasive solutions for chronic nasal conditions, specifically chronic rhinitis. Its flagship product, NEUROMARK, targets the overactive posterior nasal nerves to provide durable relief for patients suffering from this prevalent condition, which affects millions globally and often has limited treatment options. Founded in 2014 and based in Galway, the company leverages advances in neurostimulation and ablation to offer a procedure that is both effective and patient-friendly, potentially reducing reliance on medications or more invasive surgeries. NEUROMARK represents a significant innovation in the rhinitis treatment landscape, addressing a substantial unmet need for long-lasting, non-pharmacological therapies. As a private company, Neurent Medical has likely been progressing through preclinical and clinical development toward regulatory approvals. While specific financial and operational details are not publicly available, the company is well-positioned in the growing medical device market for ent and allergy treatments. If successful, NEUROMARK could capture a significant share of the chronic rhinitis treatment market and attract interest from larger strategic players in otolaryngology. Near-term catalysts include the completion of pivotal clinical trials and subsequent regulatory submissions in the US and Europe, which would de-risk the technology and pave the way for commercialization.

Upcoming Catalysts (preview)

• Q3 2026Pivotal Clinical Trial Results for NEUROMARK70% success
• Q1 2027FDA 510(k) Clearance or CE Mark Approval60% success
• H2 2026Strategic Partnership or Distribution Agreement50% success